We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 36

Off-Label Marketing - Industry Groups Step into the Breach
  • Reed Smith LLP
  • USA
  • August 8 2016

We have been waiting, literally for years, for the FDA to revise, clarify, update, or simply pay attention to, its off-label promotion regulatory


FDA launches "Bad Ad" initiative
  • Reed Smith LLP
  • USA
  • May 13 2010

On May 11, 2010, the Food and Drug Administration (FDA) launched a new initiative - the "Bad Ad Program" - designed to educate health care practitioners about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading


FDA launches "Bad Ad Program" to help health care providers detect, report misleading drug ads
  • Reed Smith LLP
  • USA
  • May 12 2010

On May 11, 2010, the U.S. Food and Drug Administration (FDA) launched a new initiative the “Bad Ad Program” designed to educate health care practitioners about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading


HITECH privacy and security regulations currently being drafted
  • Reed Smith LLP
  • USA
  • March 17 2010

The Health Information Privacy page of the U.S. Department of Health and Human Services (HHS) website has formally announced that regulations implementing the privacy and security provisions of the Health Information Technology for Economic and Clinical Health (HITECH) Act will soon be published (along with a comment period) relating to business associate liability


FDA seeks to understand social media
  • Reed Smith LLP
  • USA
  • November 25 2009

Earlier this month, the Food and Drug Administration (FDA) held public hearings to better understand the role of, and the risks associated with, the promotion and marketing of FDA-regulated products using the Internet and social media


FDA discusses social media advertising regulation for the life sciences industry
  • Reed Smith LLP
  • USA
  • November 17 2009

On November 12 and 13, 2009, the FDA hosted public hearings to vet the potential need for regulation of prescription pharmaceutical and medical device marketing on social media outlets such as YouTube, Wikipedia, Facebook, and Twitter


Pharmaceutical package: safe, innovative and accessible medicines and a renewed vision for the pharmaceutical sector
  • Reed Smith LLP
  • European Union
  • February 5 2009

The European Commission published on December 10, 2008 a series of political measures and legislative proposals, the so-called “Pharmaceutical Package.”


Maximizing patent term extension for a drug product based upon FDA review
  • Reed Smith LLP
  • USA
  • July 13 2007

Patenting newly developed drug products is the life’s blood of a branded pharmaceutical company


Advertising & marketing to children
  • Reed Smith LLP
  • Italy
  • February 28 2007

Advertising targeted at children and minors has become the focus of legislators and watchdogs throughout the world


Areta Kupchyk
  • Reed Smith LLP